Have you been diagnosed with Chronic Myeloid Leukemia, have a T315I mutation, and previously treated with at least two tyrosine kinase inhibitors (TKIs)? You might be able to participate in this study.

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

This study aims to understand how we can use fecal samples to measure cortisol levels in babies. Cortisol is used to measure stress biologically, and past research has used saliva or blood samples to do so. However, these measures can be hard to collect in infants, whereas diapers are relatively easy to obtain. We are aiming to determine whether cortisol in fecal samples changes throughout the day, like saliva or blood samples, or whether they are consistent like in urine. We will also use these data to investigate relationships between cortisol and composition of the gut microbiome, health, and infant distress. We are also measuring the composition of the skin microbiome to understand how the people a baby comes into contact with can affect their health.

The purpose of this research study is to compare the effectiveness of two combinations of anticancer study drugs in treating your Chronic Lymphocytic Leukemia (CLL). The first combination is sonrotoclax (also known as BGB-11417) and zanubrutinib, while the second combination is venetoclax and obinutuzumab. The aim is to determine which combination of study drugs is more effective in controlling your specific type of cancer,

This research study is being done in participants with advanced B-cell malignancies such as some types of lymphomas or leukemias. B-cell malignancies express a protein called the Bruton's tyrosine kinase (BTK), which has been shown to help the tumor cells grow and survive. The investigational drug, AC676, has been designed to recognize the BTK protein, and marks it for destruction. By destroying the BTK protein, the malignancy may be stopped from growing. "Investigational" means the study drug being tested is not approved by the FDA. This is an open-label study, meaning all patients who are eligible to participate will receive study drug. The key purposes of this study are to: ● Test the study drug at different dose levels (dose-escalation) and to determine the highest dose that can be taken without side effects that can't be tolerated (referred to as maximum tolerated dose or MTD). ● Determine what dose of

Are you a male that has been diagnosed with hormone receptor positive and HER2 negative breast cancer? If so, you may be eligible to a clinical trial comparing different endocrine therapies to treat breast cancer prior to surgery.

The purpose of this study is to better understand the experiences of Black Americans who have psychosis and who use substances. We are interested in understanding how people think about and experience recovery, and how these experiences may be shaped by the ways people view themselves. Potential participants will complete a 15-minute screening session to determine their eligibility for the study.

Interested in creativity and emotion regulation? If you're over 18, you may be able to participate in a study to learn about factors that shape creativity and emotion regulation. All participants entered into a drawing for one of four $50 AMEX gift cards. Immigrants and second-generation individuals are particularly encouraged to participate.

Have you been diagnosed with metastatic breast cancer? If so, you may be able to take part in a research study looking at the efficacy of giving a drug called enzalutamide, alone or combined with mifepristone vs standard chemotherapy.

Have you been diagnosed with Smoldering Multiple Myeloma (SMM)? Are you 40 years old or older? If so, you may be able to participate in a study to see if AL-related genes can increase the chances of SMM patients developing AL Amyloidosis in the future.